Certificate of Competence in Breast Cancer - fourth cohort (CCB4)
04.05.2021 - 23.07.2022
APPLICATION CLOSED
POSTGRADUATE PROGRAMME
Block 2
10.05.2021 - 31.07.2021
CCB4: Module 1: Epidemiology and prevention, biology and clinical trials
Programme
10 May | ||
| 0:00 | Epidemiology and risk factors Adam Brentnall, UK | |
| 0:00 | Breast cancer prevention: Pharmaco-prevention Jack Cuzick, UK | |
| 0:00 | Breast cancer prevention: Lifestyle changes Matti Rookus, NL | |
| 0:00 | Pathology of invasive breast cancer Emad Rakha, UK | |
| 0:00 | Prognostic and predictive markers Ivana Sestak, UK | |
| 0:00 | Intratumor heterogeneity Giancarlo Pruneri, IT | |
| 0:00 | PI3K/AKT/mTOR pathway signalling; ER pathway and cell cycle Giuseppe Curigliano, IT | |
| 0:00 | Inflammatory breast cancer Steven van Laere, BE | |
| 0:00 | Pathology of rare breast cancer subtypes Tibor Tot, SE | |
| 0:00 | Molecular portraits, risk of recurrence scores and clinical relevant genomic features of breast cancer John Martens, NL | |
| 0:00 | Local relapse patterns Isabel T. Rubio, ES | |
| 0:00 | Dissemination and organ specific metastasis according to subtype Roger Gomis, ES | |
| 0:00 | Circulating tumor cells Klaus Pantel, DE | |
| 0:00 | Principles of clinical trials: design and interpretation; design of biomarker driven neoadjuvant trials Marc Buyse, BE | |
| 0:00 | Biostatistics Vincenzo Bagnardi, IT | |
| 0:00 | Planning and performance of clinical trials (introduction into good clinical practice) Anita Hiltbrunner, CH | |
| 0:00 | Management of a clinical trial database Liv Meert, BE | |
| 0:00 | Transfer of study results into clinical practice | |
| 0:00 | The challenge of translational research: Integrating molecular biology within clinical trials Matthew J. Ellis, US | |
| 0:00 | The challenge of translational research: Management of biobanks | |
| 0:00 | The challenge of translational research: Management of biobanks Peter Riegman, NL | |
| 0:00 | Major meta-analysis collaboration in breast cancer Richard Gray, UK | |
Faculty
Vincenzo Bagnardi, Milan University, Dept. of Statistics ansd Quantative Methodology, Milan, IT
Adam Brentnall, Queen Mary University of London, Wolfson Institute of Preventative Medicine, Centre for Cancer Prevention, London, UK
Marc Buyse, IDDI & CluePoints, ., Louvain-la-Neuve, BE
Giuseppe Curigliano, European Institute of Oncology / University of Milan, New Drugs for Innovative Therapies Division, Milano, IT
Jack Cuzick, Queen Mary University of London, Wolfson Institute of Preventive Medicine, Centre for Cancer Prevention, London, UK
Matthew J. Ellis, Lester and Sue Smith Breast Center, Baylor Clinic, Houston, US
Roger Gomis, Institute for Research in Biomedicine, Growth Control and Cancer Metastasis Programme, Barcelona, ES
Richard Gray, University of Oxford, Nuffield Dept. of Population Health, Oxford, UK
Anita Hiltbrunner, IBCSG/ETOP, Director, Bern, CH
John Martens, Erasmus MC, Dept. of Oncology, Rotterdam, NL
Liv Meert, EORTC, Data Management Dept., Brussels, BE
Klaus Pantel, University Medical Center Hamburg-Eppendorf, Institute of Tumor Biology, Hamburg, DE
Giancarlo Pruneri, National Cancer Institute, IRCCS Foundation, Pathology Dpt., Milano, IT
Emad Rakha, University of Nottingham and NUH NHS Trust, Dept. of Histopathology, Nottingham, UK
Peter Riegman, Erasmus MC, Pathology Department, Rotterdam, NL
Matti Rookus, Netherlands Cancer Institute, Dept. of Epidemiology, Amsterdam, NL
Isabel T. Rubio, Clínica Universidad de Navarra, Breast Surgical Oncology Dpt., Madrid, ES
Ivana Sestak, Queen Mary University of London, Wolfson Institute of Preventative Medicine, Centre for Cancer Prevention, London, UK
Tibor Tot, Dalarna Region County Hospital, Dept of Pathology and Cytology, Falun, SE
Steven van Laere, University of Antwerp, CORE, Antwerp, BE